NCT07292272 2026-03-23
Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
University of Nebraska
Phase 2 Not yet recruiting
Clinical Trials
18 trialsNCT03970096 2026-03-12
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT03708003 2025-12-30
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Phase 2 Terminated
NCT06516679 2025-07-03
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
Yonsei University
Phase 2 Recruiting
NCT03575325 2024-12-12
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT06462248 2024-06-17
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
Prince of Wales Hospital, Shatin, Hong Kong
Phase 2 Recruiting
NCT03613727 2023-11-07
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Virginia Commonwealth University
Phase 2 Completed
NCT06111625 2023-11-01
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Sichuan University
Phase 2 Recruiting
NCT06075238 2023-10-10
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
Sichuan University
Phase 2 Not yet recruiting
NCT01754857 2023-06-27
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
University of Wisconsin, Madison
Phase 2 Completed
NCT02593123 2023-01-23
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
Phase 2 Completed
NCT04155840 2022-04-11
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
University of Washington
Phase 2 Terminated
NCT02481297 2020-05-28
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01116193 2017-09-14
RV-405 LAL
Institut de Cancérologie de la Loire
Phase 2 Completed
NCT00683046 2016-11-22
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Phase 2 Completed
NCT00609869 2015-09-17
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00006092 2012-09-26
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00801580 2009-09-15
My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia
University of Bologna
Phase 2 Unknown